AbbVie receives EU approval for Rinvoq to treat pediatric arthritis
AbbVie (ABBV:NYSE) announced that its drug Rinvoq has received European Union regulatory approval for the treatment of active polyarticular juvenile idiopathic arthritis in patients aged two years and older. This approval is intended for those who have not responded adequately or are unable to tolerate conventional therapies. The expansion of Rinvoq's indication into a pediatric population marks an important milestone, potentially broadening its market reach within Europe. Juvenile idiopathic arthritis affects thousands of children annually, making this new therapeutic option significant in the rheumatology space. This regulatory approval could enhance AbbVie’s revenue potential and strengthen its position as a leader in innovative treatments for autoimmune diseases.
Tickers: $ABBV